What does this research mean for the field?

The VISITECT CD4 lateral flow assay is a highly sensitive point-of-care tool for screening advanced HIV disease, though its visual design limits specificity, which is reader-dependent and improves with training. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the diagnostic performance and reader variability of the VISITECT CD4 lateral flow assay for identifying advanced HIV disease (CD4 ≤ 200 cells/μL) in routine clinical practice.

August 22, 2026Journal of Clinical Laboratory AnalysisOpen Access

Performance Evaluation of the VISITECT CD4 Lateral Flow Point‐Of‐Care Assay for Identifying Advanced HIV Disease

View Full Paper

Ask AI

Bookmark

Authors

MAMariana AndreaniFernandez Hospital CFClaudia FrolaHospital Fernández LGLiliana GuelfandHospital Fernández

Discussion

Member takes

Implication

Diagnostic evaluation reveals high sensitivity but low specificity for a point-of-care CD4 assay in HIV, highlighting the need for reader-independent interpretation.

Key Points

To evaluate the diagnostic performance and reader variability of the VISITECT CD4 lateral flow assay for identifying advanced HIV disease (CD4 ≤ 200 cells/μL) in routine clinical practice.
Conducted a two-phase diagnostic evaluation in Argentina (N = 349 total; training phase n = 100, validation phase n = 249) comparing the VISITECT CD4 lateral flow assay to reference flow cytometry.
Calculated sensitivity, specificity, and accuracy using manufacturer cut-offs alongside receiver operating characteristic (ROC) curves to evaluate implicit reader thresholds.
VISITECT CD4-LFA demonstrated 100% sensitivity (95% CI 94–100) across both the training and validation phases.
Specificity rose from 19% (95% CI 8–35) in the training phase to 40% (95% CI 31–49) in the validation phase, with overall accuracy increasing from 42% (95% CI 33–53) to 57% (95% CI 51–63).
ROC analysis showed the implicit reader cut-off shifted from 363 to 270 cells/μL, reflecting improved visual interpretation with experience.

Cite This Study

Andreani et al. (2026) studied this question.

synapsesocial.com/papers/6a895eaeca7ade938187cd2d https://doi.org/10.1002/jcla.70340

View Full Paper

Ask AI

Bookmark

Implication

Diagnostic evaluation reveals high sensitivity but low specificity for a point-of-care CD4 assay in HIV, highlighting the need for reader-independent interpretation.

Performance Evaluation of the VISITECT CD4 Lateral Flow Point‐Of‐Care Assay for Identifying Advanced HIV Disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Performance Evaluation of the VISITECT CD4 Lateral Flow Point‐Of‐Care Assay for Identifying Advanced HIV Disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider